RPS6KA3

Across TCGA pan-cancer cohorts, RPS6KA3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RPS6KA3 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RPS6KA3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPS6KA3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and COAD are the cancer types where RPS6KA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	1.000	0.660	<.001	59	view →
PDAC	OS	Quartile	All	0.562	0.284	<.001	43	view →
COAD	DFS	Tertile	All	1.000	0.914	.047	12	view →
LUAD	OS	Tertile	II,III,IV	0.702	0.284	.008	6	view →
HNSC	OS	Median	II,III,IV	0.933	0.992	.024	3	view →
GBM	DFS	Quartile	All	0.582	0.842	.036	3	view →
LSCC	OS	Median	All	0.928	0.843	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RPS6KA3–CCRCC (DFS)

Open the CCRCC breakdown →